01—Abstract
Summary
Summary of the 10-K filed February 18, 2011. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2010 Form 10-K highlights a year of solid growth, with total net sales increasing by 9% to $7.32 billiona.
This growth was driven by a combination of increased unit volume, strategic acquisitions, and favorable foreign currency exchange rates, partially offset by pricing changes. The company's performance was supported by strong sales in both its Orthopaedic Implants and MedSurg Equipment segments. The Orthopaedic Implants segment saw a 5%b increase in sales, primarily driven by hip, knee, and trauma implant systems, while the MedSurg Equipment segment experienced a significant 16% jump, bolstered by surgical equipment, navigation systems, and patient handling products.
The company also made strategic acquisitions throughout the year, including key assets in the neurovascular market, which are expected to enhance its product portfolio and market presence. Financially, Stryker demonstrated robust operational cash flow and a strong balance sheet, enabling it to fund acquisitions, dividends, and stock repurchases. Despite some ongoing legal and regulatory matters, the company maintained effective internal controls and expressed confidence in its ability to fund future operations and growth initiatives.
02—Key points
Key Highlights
- Stryker reported a 9% increase in net sales for 2010, reaching $7.32 billion, driven by strong performance in both major business segments.
- The MedSurg Equipment segment showed particularly robust growth, with sales up 16%, driven by surgical equipment and patient handling products.
- The company completed several strategic acquisitions during 2010, including significant assets in the neurovascular market, bolstering its product offerings.
- Net earnings increased by 15% year-over-year, reaching $1.27 billion, with diluted EPS growing to $3.19.
- Operational cash flow remained strong, providing ample resources for investments in R&D, acquisitions, and shareholder returns (dividends and share repurchases).
- Research and development expenses increased to 5.4% of sales, indicating a continued focus on innovation and new product development.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2010, Stryker Corp kept $0.17.
- Revenue$7.32B100.0%
- Cost of revenue−$2.29B31.2%
- Gross profit$5.03B68.8%
- Operating costs−$3.28B44.8%
- Operating income$1.75B23.9%
- Interest, other & tax−$478.0M6.5%
- Net income$1.27B17.4%
Where FY2010 revenue went
$7.32B- SG&A: $2.71B, 37% of revenue
- Cost of revenue: $2.29B, 31% of revenue
- Net income: $1.27B, 17% of revenue
- R&D: $394.0M, 5.4% of revenue
- Other operating costs: $182.0M, 2.5% of revenue
- Interest, other & tax: $478.0M, 6.5% of revenue
Kept 17% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 18, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $7.32B$6.72B | +8.9% |
| Cost of Revenue | $2.29B$2.18B | +4.7% |
| Gross Profit | $5.03B$4.54B | +10.9% |
| R&D Expenses | $394.00M$336.00M | +17.3% |
| SG&A Expenses | $2.71B$2.51B | +8.0% |
| Operating Expenses | $3.28B$2.94B | +11.5% |
| Operating Income | $1.75B$1.59B | +9.8% |
| Interest Expense | $53.00M$14.00M | +278.6% |
| Net Income | $1.27B$1.11B | +15.0% |
| EPS (Basic) | $3.21$2.79 | +15.1% |
| EPS (Diluted) | $3.19$2.77 | +15.2% |
| Shares Outstanding (Basic) | 396.40M397.40M | −0.3% |
| Shares Outstanding (Diluted) | 399.50M399.40M | 0.0% |
05—Questions
Frequently Asked Questions
What were Stryker's primary revenue drivers in 2010?
Stryker's revenue in 2010 was primarily driven by its two core segments: Orthopaedic Implants and MedSurg Equipment. Within Orthopaedic Implants, growth was seen in hip, knee, and trauma implant systems. The MedSurg Equipment segment's strong performance was led by surgical equipment, navigation systems, endoscopic and communications systems, and patient handling and emergency medical equipment.
What significant strategic moves did Stryker make in 2010 regarding acquisitions or divestitures?
In 2010, Stryker completed several acquisitions, including assets for the Sonopet Ultrasonic Aspirator, Gaymar Industries, and the bioimplantable implants product line from Porex Surgical. Notably, they announced and subsequently completed the acquisition of the Neurovascular division of Boston Scientific Corporation for $1.45 billion in early 2011, significantly expanding their presence in the neurovascular market. They also announced the sale of their OP-1 product family, which was completed in February 2011.
How did Stryker's financial performance, particularly regarding profitability and cash flow, look in 2010?
Stryker demonstrated strong financial performance in 2010. Net sales increased 9% to $7.32 billion, and net earnings grew 15% to $1.27 billion, with diluted EPS at $3.19. The company generated robust net cash from operating activities of $1.55 billion, providing flexibility for its strategic initiatives, including acquisitions and returning capital to shareholders through dividends and share repurchases.
What are some of the key risks that Stryker identified in its 2010 10-K filing?
Stryker highlighted several risks, including the potential negative impact of economic and political developments in countries where it operates, stricter pricing guidelines in the medical technology industry, product liability claims and regulatory compliance issues, the ability to maintain relationships with healthcare professionals, potential changes in income tax allocations, and the successful capitalization on R&D spending and previous or future acquisitions.
06—Continue